Not applicableNo Longer AvailableNCT04518644What this trial is testingNilotinib, for Patients With CML-CP or CML-APWho this might be right forChronic Myelogenous Leukemia (CML) Novartis Pharmaceuticals
Large-scale testing (Phase 3)Study completedNCT01511289What this trial is testingRadotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase PatientsWho this might be right forLeukemiaLeukemia, MyeloidLeukemia, Myelogenous, Chronic, BCR-ABL Positive+3 more Il-Yang Pharm. Co., Ltd. 242
Large-scale testing (Phase 3)Study completedNCT01743989What this trial is testingPhase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML.Who this might be right forPhiladelphia Chromosome Positive (PH+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Novartis Pharmaceuticals 620
Large-scale testing (Phase 3)Active Not RecruitingNCT05456191What this trial is testingInvestigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)Who this might be right forPhiladelphia Chromosome-Positive Chronic Myeloid Leukemia Novartis Pharmaceuticals 568
Post-approval studies (Phase 4)Study completedNCT06427811What this trial is testingClinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I MutationWho this might be right forPhiladelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Novartis Pharmaceuticals 85
Early research (Phase 1)Study completedNCT01220648What this trial is testingDetermining the Maximum Tolerated Dose of Low Dose Interferon-alpha in Conjunction With Nilotinib in Pretreated Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP)Who this might be right forChronic Myeloid Leukemia Novartis Pharmaceuticals 4
Post-approval studies (Phase 4)Study completedNCT03332511What this trial is testingEfficacy and Safety of Nilotinib in CML-CPWho this might be right forChronic Myeloid Leukemia, Chronic Phase Seoul National University Hospital 110
Testing effectiveness (Phase 2)UnknownNCT01503502What this trial is testingA Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous LeukemiaWho this might be right forMyelogenous Leukemia, Chronic Jiangsu HengRui Medicine Co., Ltd. 150
Not applicableStudy completedNCT03509896What this trial is testingStudy of Chinese Newly Diagnosed Participants With Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP)Who this might be right forChronic Myeloid LeukemiaPhiladelphia ChromosomeChronic Myeloid Leukemia in Chronic Phase Bristol-Myers Squibb 463
Post-approval studies (Phase 4)Study completedNCT01227577What this trial is testingCMR Rate of Newly Diagnosed CML-CP Patients Treated With NilotinibWho this might be right forChronic Myelogenous Leukemia in Chronic Phase Novartis Pharmaceuticals 128
Testing effectiveness (Phase 2)Looking for participantsNCT05007873What this trial is testingASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic PhaseWho this might be right forChronic Phase Chronic Myelogenous LeukemiaPhiladelphia Chromosome PositiveBCR-ABL1 Positive Chronic Myelogenous Leukemia+1 more M.D. Anderson Cancer Center 70
Large-scale testing (Phase 3)Study completedNCT00333840What this trial is testingSafety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous LeukemiaWho this might be right forChronic Myelogenous Leukemia Novartis Pharmaceuticals 1,106
Post-approval studies (Phase 4)Study completedNCT01043874What this trial is testingStudy to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal ResponseWho this might be right forPhiladelphia Chromosome PositiveChronic Myelogenous Leukemia in Chronic Phase Novartis Pharmaceuticals 45
Post-approval studies (Phase 4)Study completedNCT01735955What this trial is testingStudy to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored StudyWho this might be right forChronic Myelogenous Leukemia (CML)Metastatic Gastrointestinal Stromal Tumors (GIST)Acute Lymphoblastic Leukemia (ALL)+1 more Novartis Pharmaceuticals 57
Large-scale testing (Phase 3)Study completedNCT00006343What this trial is testingSTI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous LeukemiaWho this might be right forLeukemia Novartis
Large-scale testing (Phase 3)Study completedNCT01275196What this trial is testingSafety and Efficacy of Nilotinib vs. Imatinib in the Treatment of Newly Diagnosed Chinese Ph+ CML-CP PatientsWho this might be right forChronic Myeloid Leukemia Novartis Pharmaceuticals 267
Large-scale testing (Phase 3)Temporarily pausedNCT01755325What this trial is testingPhase III Study of Compound Formula Realgar-Indigo Naturalis Plus Imatinib Versus Placebo Plus Imatinib in Adult CML-CP Patients With Ph+Who this might be right forChronic Myelogenous Leukemia Junmin Li 680
Post-approval studies (Phase 4)Study completedNCT00980018What this trial is testingAn Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib TreatmentWho this might be right forChronic Myelogenous Leukemia Novartis Pharmaceuticals 52
Testing effectiveness (Phase 2)Study completedNCT00809211What this trial is testingNilotinib in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous LeukemiaWho this might be right forLeukemia Cancer Trials Ireland 40
Large-scale testing (Phase 3)Active Not RecruitingNCT04971226What this trial is testingOral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CPWho this might be right forChronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive Novartis Pharmaceuticals 405